What are Mission Vision & Core Values of Edwards Lifesciences Company?

The Edwards Lifesciences Mission explicitly centers on "people fighting cardiovascular disease." This patient-centric approach is the cornerstone of their operations. Their commitment extends to improving the quality of life for those affected by these conditions.

Edwards Lifesciences is dedicated to providing "innovative solutions." This highlights their commitment to research, development, and the creation of cutting-edge medical technologies. They focus on addressing unmet needs in cardiovascular care.

The mission statement emphasizes improving the "quality of life around the world." This global perspective underscores Edwards Lifesciences' ambition to reach patients worldwide. Their products and services aim to make a significant impact on a global scale.

Edwards Lifesciences strives to be "trusted partners" with customers, colleagues, and patients. This signifies their dedication to building strong relationships. They aim to foster a collaborative environment focused on shared goals.

The company vows to "act boldly, decisively, and with determination." This highlights their proactive approach to addressing cardiovascular disease. They are committed to making a tangible difference in patients' lives.

Their results will benefit customers, patients, employees, and shareholders. This demonstrates a balanced approach to success. They aim to create value for all stakeholders involved in their operations.

The vision statement is distinctly future-oriented, focusing on leadership in the provision of innovative solutions for cardiovascular disease. It's a clear indication of the company's strategic direction and its commitment to staying at the forefront of medical advancements. This forward-thinking approach is crucial in the rapidly evolving healthcare sector.

The scope of the vision extends beyond mere product offerings; it encompasses industry disruption through 'breakthrough technologies.' This indicates Edwards Lifesciences' commitment to not just incremental improvements, but to truly transformative innovations. This focus on innovation is central to achieving their mission and realizing their vision.

The vision also emphasizes a global impact by delivering 'life-changing innovations to those who need them most.' This highlights Edwards Lifesciences' commitment to improving patient outcomes worldwide. This patient-focused approach is a key element of the company's Edwards Lifesciences Mission and overall strategy.

The ambition for market leadership is explicit in their goal to be 'the leading provider.' This ambitious target underscores Edwards Lifesciences' drive for excellence and its desire to set the standard within the cardiovascular solutions market. Achieving this goal is a key indicator of their success.

Considering the company's current trajectory and market position, the vision appears both realistic and aspirational. Edwards Lifesciences has demonstrated consistent financial health, with a 9% organic sales growth in 2024. Their strategic focus on structural heart disease, particularly TAVR, positions them well for future growth. Furthermore, their commitment to R&D, with $1.05 billion in expenses in 2024, supports the innovation-driven vision.

Edwards Lifesciences projects a 2025 constant currency sales growth of 8% to 10%, aiming for an average annual total company sales growth of 10% and double-digit EPS growth beyond 2026. These projections indicate a clear path towards achieving their aspirational goals and underscore the company's confidence in its future. For more insights, consider reading about the Marketing Strategy of Edwards Lifesciences.

The Edwards Lifesciences vision of advancing breakthrough technologies is evident in its robust product development and innovation pipeline. The company's focus on Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) exemplifies this commitment. The success of these innovation-driven strategies is reflected in the financial results.

In Q4 2024, TAVR sales grew by 6% to $1.04 billion, and TMTT sales surged by 88% to $105 million. Ongoing clinical trials like EARLY TAVR and TRISCEND II, along with the expected mid-year asymptomatic TAVR indication approval in the U.S. in 2025, demonstrate the company's dedication to advancing science and expanding patient access. These advancements are a direct result of the company's mission and vision.

Edwards Lifesciences' global ambition is directly guided by its vision, extending its reach to over 100 countries. The company's commitment to expanding access to its surgical innovations in emerging markets in 2025 further demonstrates this global ambition. The Every Heartbeat Matters initiative is on track to impact 2.5 million underserved structural heart patients by the end of 2025, showcasing its commitment to addressing global health disparities.

The company's mission and vision shape day-to-day operations and long-term planning by fostering a patient-focused culture. CEO Bernard Zovighian's statement highlights the leadership's commitment to a patient-centric approach across the organization. Robust supplier engagement and partnerships with key suppliers to manage risk and ensure product quality also reflect their commitment to delivering high-quality products that align with their mission.

Edwards Lifesciences projects 2025 constant currency sales growth of 8% to 10% and aims for an average annual total company sales growth of 10% and double-digit EPS growth beyond 2026. This demonstrates clear long-term planning driven by their strategic focus. The company's commitment to its mission and vision is evident in its financial projections and strategic objectives.

Edwards Lifesciences' robust supplier engagement program and partnerships with key suppliers to manage risk and ensure product quality also reflect their commitment to delivering high-quality products that align with their mission. This focus on quality and risk management is crucial for maintaining the company's reputation and ensuring patient safety. The company's commitment to its mission is also reflected in its ethical guidelines.

Leadership plays a vital role in reinforcing the Edwards Lifesciences Mission and Edwards Lifesciences Core Values throughout the organization.

Bernard Zovighian, CEO, consistently highlights the company's patient-focused culture and commitment to innovation, ensuring these principles are actionable for all employees.

Edwards Lifesciences communicates its mission and values through various channels to all stakeholders. Their annual Corporate Impact Report details their commitment to patients, products, people, planet, and governance & ethics.

Patient Experience events, held in 12 countries in 2024, foster direct engagement between patients, employees, and partners, reinforcing the patient-first value.

The company's commitment to its Mission Statement is evident through concrete actions.

Significant investment in research and development, reaching $1.05 billion in 2024, demonstrates a strong commitment to innovation. The Every Heartbeat Matters initiative aims to impact 2.5 million underserved structural heart patients by the end of 2025, showcasing global impact.

Edwards Lifesciences uses formal programs to ensure alignment with its Company Values.

Comprehensive environmental, social, and governance (ESG) practices, as detailed in their corporate impact report, demonstrate a structured approach to responsible business conduct. Their robust supplier engagement program ensures partners align with quality and safety standards. For more information on Edwards Lifesciences' business model, consider reading this article on Revenue Streams & Business Model of Edwards Lifesciences.